Our Pricing

Weight Loss Injection Treatment UK: Expert Clinical Guide

Published on: June 03, 2026

Looking for effective weight loss injection treatment UK online with transparent pricing and expert clinical support? At Cured Pharmacy, we provide MHRA-licensed injectable treatments including Mounjaro, Wegovy, and Saxenda, with free online consultations from UK-registered prescribers and discreet home delivery across the United Kingdom.

How Weight Loss Injection Treatment UK Works

Weight loss injections available in the UK work by mimicking natural gut hormones called incretins, which regulate appetite and blood sugar control [1]. These medications — including tirzepatide (Mounjaro), semaglutide (Wegovy), and liraglutide (Saxenda) — are GLP-1 receptor agonists that signal fullness to the brain, slow gastric emptying, and reduce food cravings.

Clinical trials have demonstrated substantial weight reduction when these injections are combined with lifestyle modifications. The STEP programme showed that semaglutide produced an average 14.9% body weight reduction over 68 weeks, whilst the SURMOUNT-1 trial demonstrated tirzepatide achieved up to 22.5% weight loss over 72 weeks in participants with obesity [1][2]. These results represent significantly greater efficacy than older weight management approaches.

All prescription weight loss injections require clinical assessment by a UK-registered prescriber before dispensing. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) and clinical team ensure every patient receives appropriate treatment based on their medical history, current medications, and weight management goals.

Mounjaro Weight Loss Injections: Dual-Action Treatment

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in the UK [2]. Unlike single-pathway treatments, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, producing enhanced metabolic effects.

In the SURMOUNT clinical trial programme, participants taking the 15mg maintenance dose of tirzepatide achieved an average body weight reduction of 22.5% over 72 weeks — the highest efficacy demonstrated in obesity pharmacotherapy to date [2]. The dual-receptor mechanism appears to provide superior appetite suppression and improved glycaemic control compared to GLP-1-only alternatives.

Mounjaro is administered as a once-weekly subcutaneous injection using the convenient KwikPen device. Treatment typically begins at 2.5mg weekly, with gradual dose escalation every four weeks to minimise gastrointestinal side effects. At Cured Pharmacy, Mounjaro is available from £135.00, subject to prescriber approval following your free online consultation.

Who Can Use Mounjaro in the UK?

Mounjaro is licensed for adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity such as hypertension or type 2 diabetes [3]. Your UK prescriber will assess your eligibility during the online consultation, reviewing your medical history, current medications, and any contraindications including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Wegovy and Saxenda: Semaglutide and Liraglutide Options

Wegovy contains semaglutide, a GLP-1 receptor agonist that has been extensively studied in the STEP clinical trial programme. In STEP 1, participants achieved an average 14.9% body weight reduction over 68 weeks, with 86.4% of patients losing at least 5% of their baseline weight [1]. Wegovy is administered once weekly and offers a well-established safety profile backed by years of clinical use.

Saxenda contains liraglutide, a daily injectable GLP-1 treatment that has been available in the UK since 2015. Whilst requiring daily administration rather than weekly dosing, Saxenda provides a lower-cost entry point for patients beginning weight loss injection treatment. Clinical trials showed an average 8% body weight reduction over 56 weeks when combined with lifestyle intervention [4].

Both medications require gradual dose titration to minimise common side effects including nausea, vomiting, and diarrhoea. Your UK prescriber will determine the most appropriate treatment based on your individual circumstances, previous weight loss attempts, and tolerance for injection frequency.

Choosing Between Weekly and Daily Injections

Weekly injections like Mounjaro and Wegovy offer greater convenience and improved adherence for many patients, whilst daily Saxenda injections provide more gradual hormone exposure that some individuals tolerate better. Your prescriber will discuss the practical considerations, including your lifestyle, previous experience with injectable medications, and treatment goals during your clinical assessment.

Weight Loss Injection Treatment UK: Expected Results and Timeline

Weight loss with injectable GLP-1 treatments occurs gradually over several months as your body adjusts to reduced appetite and caloric intake. Most patients begin noticing appetite suppression within the first two weeks, with measurable weight reduction typically evident by week four to eight [1][2].

Clinical trial data demonstrates that maximum weight loss generally occurs between 60 and 72 weeks of continuous treatment, though individual results vary considerably based on adherence, dietary modifications, physical activity levels, and metabolic factors [2]. Patients who combine injection therapy with structured lifestyle changes — including reduced caloric intake and increased physical activity — achieve significantly better outcomes than medication alone.

It's important to maintain realistic expectations: whilst clinical trials show impressive average results, individual responses range widely. Some patients may experience 25% body weight reduction, whilst others achieve more modest results. Your UK prescriber will monitor your progress through follow-up consultations, adjusting dosage or treatment approach as needed to optimise outcomes whilst minimising side effects.

Side Effects and Safety Considerations for Weight Loss Injections

The most common side effects of GLP-1 weight loss injections are gastrointestinal, including nausea, vomiting, diarrhoea, constipation, and abdominal discomfort [1][2]. These effects are typically most pronounced during dose escalation and often diminish as your body adapts to treatment. Eating smaller, more frequent meals and avoiding high-fat foods can help minimise digestive symptoms.

Serious but rare side effects include pancreatitis, gallbladder disease, and hypoglycaemia (particularly in patients taking diabetes medications concurrently). All GLP-1 treatments carry a boxed warning regarding thyroid C-cell tumours observed in rodent studies, though no causal relationship has been established in humans [3]. These medications are contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Your UK prescriber will review your complete medical history during consultation to identify any contraindications or risk factors. Patients with a history of severe gastrointestinal disease, diabetic retinopathy, or renal impairment require particularly careful assessment. All prescription weight loss treatments at Cured Pharmacy are dispensed only after thorough clinical evaluation by our UK-registered medical team.

Managing Common Side Effects

Most gastrointestinal side effects can be managed through dietary modifications, slower eating, and adequate hydration. If you experience persistent vomiting, severe abdominal pain, or signs of pancreatitis (severe upper abdominal pain radiating to the back), contact your prescriber immediately. Our clinical team at Cured Pharmacy provides ongoing support throughout your treatment journey, with guidance available via phone on (+44) 116 4646009.

Getting Weight Loss Injection Treatment UK at Cured Pharmacy

Starting your weight loss injection treatment at Cured Pharmacy is straightforward and fully compliant with UK pharmaceutical regulations. Begin by completing our free online consultation, which takes under three minutes and covers your medical history, current medications, weight management goals, and any contraindications. This assessment is reviewed by a UK-registered prescriber who will determine the most appropriate treatment for your individual circumstances.

If approved, your prescription is sent directly to our GPhC-registered pharmacy (registration number 9012511), where our team dispenses genuine UK-licensed medications in discreet packaging. We offer competitive pricing across our weight loss range, with transparent costs displayed before you complete your consultation — no hidden fees or surprise charges at checkout.

All orders are dispatched via tracked courier for secure delivery to your home address. We maintain the lowest prices guaranteed in the UK whilst never compromising on medication quality or clinical standards. Every product dispensed is sourced through licensed UK wholesalers and stored in our temperature-controlled pharmacy facility to ensure optimal efficacy and safety.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
3. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. GOV.UK. https://products.mhra.gov.uk/ [accessed 13 August 2026]
4. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to treatment, lifestyle modifications, and individual metabolic factors.